1. QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019
- Author
-
Neal A. Chatterjee, Basil Saour, Jeanne E. Poole, Christine Johnston, Elizabeth A. Starnes, Dan Nguyen, Gregory A. Roth, Arun Sridhar, and Margaret L. Green
- Subjects
QT interval ,medicine.medical_specialty ,coronavirus ,Context (language use) ,Disease ,electrocardiogram ,Azithromycin ,Article ,chemistry.chemical_compound ,Interquartile range ,Internal medicine ,medicine ,Clinical endpoint ,Diseases of the circulatory (Cardiovascular) system ,cardiovascular diseases ,ventricular arrhythmia ,Creatinine ,business.industry ,Hydroxychloroquine ,chemistry ,RC666-701 ,Cardiology ,cardiovascular system ,business ,medicine.drug - Abstract
Background Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). Objective The arrhythmic safety profile of HCQ monotherapy, which remains under investigation as a therapeutic and prophylactic agent in COVID-19, is less established and we sought to evaluate this. Methods In 245 consecutive patients with COVID-19 admitted to the University of Washington hospital system between March 9, 2020, and May 10, 2020, we identified 111 treated with HCQ monotherapy. Patients treated with HCQ underwent a systematic arrhythmia and QT interval surveillance protocol including serial electrocardiograms (ECG) (baseline, following second HCQ dose). The primary endpoint was in-hospital sustained ventricular arrhythmia or arrhythmic cardiac arrest. Secondary endpoints included clinically significant QTc prolongation. Results A total of 111 patients with COVID-19 underwent treatment with HCQ monotherapy (mean age 62 ± 16 years, 44 women [39%], serum creatinine 0.9 [interquartile range 0.4] mg/dL). There were no instances of sustained ventricular arrythmia or arrhythmic cardiac arrest. In 75 patients with serial ECGs, clinically significant corrected QT (QTc) prolongation was observed in a minority (n = 5 [7%]). In patients with serial ECGs, there was no significant change in the QTc interval in prespecified subgroups of interest, including those with prevalent cardiovascular disease or baseline use of renin-angiotensin-aldosterone axis inhibitors. Conclusions In the context of a systematic monitoring protocol, HCQ monotherapy in hospitalized COVID-19 patients was not associated with malignant ventricular arrhythmia. A minority of patients demonstrated clinically significant QTc prolongation during HCQ therapy.
- Published
- 2020